NeoGenomics Announces Six Clinical Data Presentations to be Made at the American Society of Hematology Meeting

Download as PDF

FORT MYERS, FL -- (Marketwired) -- 12/06/17 -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that its physicians and scientists will present four posters and deliver two oral presentations at the American Society of Hematology's Annual Meeting. The presentations will highlight NeoGenomics' experience with liquid biopsy testing, and characterization of mutational profiles in the context of hematological disease clonal evolution and progression.

The analyses were done using novel approaches to analyze cell-free DNA/RNA and variant allele frequency. The diseases to be discussed include Myelodysplastic Syndrome, Clonal Hematopoiesis of Indeterminate Potential (CHIP), and Acute Myeloid Leukemia.

NeoGenomics Chairman and CEO, Douglas VanOort, said "NeoGenomics' commitment to medical and scientific research and development is evidenced by our team's presentations at this year's American Society of Hematology meeting. Clearly, our scientific advances in molecular diagnostics are providing physicians with a better understanding of cancer, and helping to improve the lives of patients."

"The presented research aims to improve prediction of clinical behavior of hematologic neoplasms to provide better tools to treating physicians for selecting therapy and improving outcomes," said Dr. Maher Albitar, Chief Medical Officer and Director of R&D, who is also the senior author of these studies.

The presentations will take place during the following times:

IDH1 and IDH2: Founding or Progressor Mutations in Myeloid Neoplasms
Number: 405, Session: 617, Time: Sunday, December 10, 12PM-1:30PM, Bldg B, Lvl 5, Murphy BR 1-2

FLT3 Mutation in Acute Myeloid Leukemia: Primary or Secondary Mutation?
Number: 2668, Session: 617, Time: Sunday, December 10, 6PM-8PM, Location: Bldg A, Lvl 1, Hall A2

Potential Familial Predisposition to Hematologic Neoplasms Detected Incidentally in Adult Patients Presenting with Myeloid Neoplasms
Number: 585, Session: 637, Time: Monday, December 11, 7AM-8:30AM, Location: Bldg C, Lvl 2, C208-C210

MDS Diagnosis Using cfDNA Profiling by Targeted Enrichment Next Generation Sequencing
Number: 4270, Session: 637, Time: Monday, December 11, 6PM-8PM, Location: Bldg A, Lvl 1, Hall A2

Clonal Hematopoiesis in Normal Individuals is Not Random and Likely Reflects Early MDS
Number: 4269, Session: 637, Time: Monday, December 11, 6PM-8PM, Location: Bldg A, Lvl 1, Hall A2

Liquid Biopsy as a Diagnostic Test for Myelodyplastic Syndromes and Other Acute and Chronic Myeloid NeoPlasms
Number: 4270, Session: 637, Time: Monday, December 11, 6PM-8PM, Location: Bldg A, Lvl 1, Hall A2

The American Society of Hematology meeting will be held from December 9-12, 2017 in Atlanta, GA at the Georgia World Congress Center. NeoGenomics will also be exhibiting at the meeting. Interested parties should stop by booth #1223 to speak with a member of the scientific team or other representative.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CLIA-certified laboratories in Aliso Viejo and Fresno, California; Tampa and Fort Myers, Florida; Houston, Texas; and Nashville, Tennessee. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit http://neogenomics.com/.

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

For further information, please contact:

NeoGenomics, Inc.
Steven C. Jones
Director of Investor Relations
(239) 325-2001
sjones@neogenomics.com

Source: NeoGenomics, Inc.

Released December 6, 2017